AGREF yields 2500.00% · JNJ yields 2.14%● Live data
📍 AGREF pulled ahead of the other in Year 1
Combined, AGREF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AGREF + JNJ for your $10,000?
Argonaut Resources NL operates as a mineral exploration and development company in Zambia and Australia. It primarily explores for iron oxide, lithium, uranium, copper, gold, cobalt, and nickel deposits. The company holds 90% interests in the Lumwana West project comprising one exploration licence; the Kamapanda project consisting of one exploration licence and covering an area of 225 square kilometers; and the Kalaba East project located in North-Western province, Zambia. It also has 80% interest in the Higginsville joint venture project covering one exploration licence located in the Eastern Goldfields of Western Australia; and holds 100% interest in the Murdie project comprising two exploration licence covering an area of 1,105 square kilometers located in Eastern Gawler Craton of South Australia. In addition, the company holds interest in the Torrens joint venture project covering one exploration licence; and the Frome project comprising three exploration licence covering an area of 2,894 square kilometers located in South Australia. Further, it holds 100% interest in the Kroombit project consisting of ML 5631 and the surrounding mineral development licence MDL 2002 located in Queensland; and the Aroona project comprising one exploration licence located in Southern Willouran Ranges, South Australia. The company was formerly known as Star Mining Corporation NL. Argonaut Resources NL was incorporated in 1985 and is based in Adelaide, Australia.
Full AGREF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.